Yhdysvallat - englanti - NLM (National Library of Medicine)

physicians total care, inc. - etravirine (unii: 0c50hw4fo1) (etravirine - unii:0c50hw4fo1) - etravirine 100 mg - intelence® 1, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in antiretroviral treatment-experienced patients ages 6 years and older, who have evidence of viral replication and hiv-1 strains resistant to a non-nucleoside reverse transcriptase inhibitor (nnrti) and other antiretroviral agents. the indication for adult use is based on week 48 analyses from 2 randomized, double-blind, placebo-controlled trials of intelence® . both studies were conducted in clinically advanced, 3-class antiretroviral (nnrti, n[t]rti, pi) treatment-experienced adults. the indication for pediatric use is based on 24-week analyses of a single-arm, phase 2 trial in antiretroviral treatment-experienced pediatric subjects 6 years to less than 18 years of age [see use in specific populations (8.4) ]. in treatment-experienced adult and pediatric patients, the following points should be considered when initiating therapy with intelence® : - treatmen

Israel - englanti - Ministry of Health

j-c health care ltd - etravirine - tablets - etravirine 200 mg - etravirine - etravirine - intelence is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in antiretroviral treatment-experienced adult patients including those with non-nucleoside reverse transcriptase inhibitor (nnrti) resistance. treatment history and when available resistance testing should guide the use of intelence. in patients who have experienced virological failure on an nnrti- and nucleoside or nucleotide reverse transcriptase inhibitor (n[t]rti)- containing regimen intelence is not recommended for use in combination with n(t)rtis only.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - etravirine 100mg - tablet - 100 mg - active: etravirine 100mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose as a spray dried powder lactose magnesium stearate microcrystalline cellulose - etravirine, in combination with other antiretroviral agents is indicated for the treatment of hiv-1 infection in antiretroviral treatment-experienced adults who have evidence of viral replication and resistance to non-nucleoside transcriptase inhibitors and other antiretroviral agents.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - etravirine 200mg - tablet - 200 mg - active: etravirine 200mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose as a spray dried powder silicified microcrystalline cellulose magnesium stearate microcrystalline cellulose - etravirine, in combination with other antiretroviral agents is indicated for the treatment of hiv-1 infection in antiretroviral treatment-experienced adults who have evidence of viral replication and resistance to non-nucleoside transcriptase inhibitors and other antiretroviral agents.

Euroopan unioni - hollanti - EMA (European Medicines Agency)

janssen-cilag international nv - etravirine - hiv-infecties - non-nucleoside reverse transcriptase inhibitors, antivirals for systemic use - intelence, in combinatie met een versterkt proteaseinhibitor en andere antiretrovirale geneesmiddelen, is geïndiceerd voor de behandeling van mens-immunodeficiëntie-virus-type 1 (hiv-1) infectie bij volwassen patiënten antiretrovirale behandeling-ervaren en in antiretrovirale behandeling-ervaren pediatrische patiënten vanaf zes jaar. deze indicatie is gebaseerd op week-48 analyses van twee fase-iii-studies in sterk voorbehandelde patiënten waar intelence werd onderzocht in combinatie met een geoptimaliseerd achtergrond regime (obr) die opgenomen darunavir/ritonavir. de indicatie bij pediatrische patiënten is gebaseerd op 48-week analyses van een enkel-arm -, fase-ii-studie in antiretrovirale behandeling ervaren pediatrische patiënten.

Kanada - ranska - Health Canada

janssen inc - Étravirine - comprimé - 100mg - Étravirine 100mg - nonnucleoside reverse transcriptase inhibitors

Kanada - ranska - Health Canada

janssen inc - Étravirine - comprimé - 200mg - Étravirine 200mg - nonnucleoside reverse transcriptase inhibitors

Kanada - ranska - Health Canada

janssen inc - Étravirine - comprimé - 25mg - Étravirine 25mg - nonnucleoside reverse transcriptase inhibitors

Israel - heprea - Ministry of Health

j-c health care ltd - etravirine - טבליה - etravirine 100 mg - etravirine - etravirine - intelence is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in antiretroviral treatment-experienced adult patients including those with non-nucleoside reverse transcriptase inhibitor (nnrti) resistance. treatment history and when available resistance testing should guide the use of intelence. in patients who have experienced virological failure on an nnrti- and nucleoside or nucleotide reverse transcriptase inhibitor (n[t]rti) - containing regimen intelence is not recommended for use in combination with n(t)rtis only.

Israel - heprea - Ministry of Health

j-c health care ltd - etravirine - טבליה - etravirine 200 mg - etravirine - etravirine - intelence is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in antiretroviral treatment-experienced adult patients including those with non-nucleoside reverse transcriptase inhibitor (nnrti) resistance. treatment history and when available resistance testing should guide the use of intelence. in patients who have experienced virological failure on an nnrti- and nucleoside or nucleotide reverse transcriptase inhibitor (n[t]rti)- containing regimen intelence is not recommended for use in combination with n(t)rtis only.